Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...

RBC Capital downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161.Don't Miss Our End of ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of March 19 at 1:57:38 PM EDT. Market Open.

After hours: March 25 at 7:57:35 p.m. EDT Loading Chart for SRPT ...

* EPS estimates are GAAP unless otherwise noted.